559P - Prognostic impact of GWAS-identified genetic variations in patients with colorectal cancer

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Colon and Rectal Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Jong Gwang Kim
Citation Annals of Oncology (2014) 25 (suppl_4): iv167-iv209. 10.1093/annonc/mdu333
Authors J.G. Kim1, Y.S. Chae1, B.W. Kang1, G.S. Choi2, S.J. Lee1, H.Y. Chung3
  • 1Hematology/oncology, Kyungpook National University Medical Center, 702-210 - Daegu/KR
  • 2Colorectal Cancer Center, Kyungpook National University Medical Center, 702-210 - Daegu/KR
  • 3General Surgery, Kyungpook National University Hospital, 702-210 - Daegu/KR



Genome-wide association studies (GWAS) have identified at least 22 single nucleotide polymorphisms that are associated with the risk of colorectal cancer. We examined the relationship between these single-nucleotide polymorphisms (SNPs) and clinical outcomes of patients with colorectal cancer.


772 patients with surgically resected colorectal adenocarcinoma were enrolled in the present study. 22 GWAS-identified SNPs were genotyped using a Sequenom MassARRAY.


Among the 22 SNPs, two SNPs (rs1321311G > T in CDKN1A and rs10411210C > T in RHPN2) were significantly associated with survival outcomes of CRC in multivariate survival analysis. In recessive model, rs1321311TT (vs. GG + GT) and rs10411210 TT genotype (vs. CC + CT) exhibited worse prognosis in disease-free survival (DFS) (adjusted HR = 2.05; 95% confidence interval = 1.11-3.78; p = 0.0022, adjusted HR =1.93; 95% confidence interval = 1.04-3.57; p = 0.037, respectively) and overall survival (OS) (adjusted HR = 2.20; 95% confidence interval = 1.12-43, p = 0.0023; adjusted HR =2.20; 95% confidence interval 1.01-3.95; p = 0.047, respectively). Other SNPs were not associated significantly with clinicopathologic features or survival.


The present results suggest that genetic variants of the CDKN1A (rs132111) and RHPN2 (rs10411210) genes could be used as prognostic biomarkers for patients with surgically resected colorectal cancer.


All authors have declared no conflicts of interest.